valsartan/amlodipine/chlorthalidone (AJU-C52L) / AJU Pharm - LARVOL DELTA

High Stakes Under Low Androgens: Amiloride Conquers Abiraterone-Driven Resistant Hypertension (KIDNEY WEEK 2025) - "Case Description A 70-year-old man with metastatic PC, diabetes (metformin), no prior HTN, began ABI + prednisone. This patient's hypertension persisted despite amlodipine, valsartan, and chlorthalidone but fell to 125/83 mmHg once amiloride, a potassium-sparing blocker of distal sodium reabsorption that does not engage the AR, replaced MRA that might blunt ABI's anticancer activity. ACEi remain useful adjuncts, yet amiloride offers an androgen-neutral strategy for controlling rHTN during ABI therapy and warrants prospective study."

Cardiovascular • Diabetes • Genito-urinary Cancer • Hormone Sensitive Prostate Cancer • Hypertension • Metabolic Disorders • Prostate Cancer • Solid Tumor • AR • CYP17A1

Efficacy and Safety of AJU-C52 in Essential Hypertension Patients (clinicaltrials.gov) - P3 | N=190 | Recruiting | Sponsor: AJU Pharm Co., Ltd.

New P3 trial • Cardiovascular • Hypertension